---
schema_version: "secwatch.filing_event.v1"
accession: "0001567264-26-000007"
form_type: "8-K"
ticker: "INTS"
cik: "0001567264"
company_name: "INTENSITY THERAPEUTICS, INC."
filed_at: "2026-02-13T23:59:59+00:00"
generated_at: "2026-05-16T02:46:44.515110+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Intensity Therapeutics to effect 1-for-25 reverse stock split on Feb 18 to meet Nasdaq bid price rule

## Summary
- Reverse split at 1-for-25 effective 4:01 p.m. ET Feb 18, 2026; post-split trading begins Feb 19.
- Pre-split shares ~63,346,579; post-split ~2,533,863; authorized shares unchanged.
- Purpose is to regain compliance with Nasdaq's $1.00 minimum bid price requirement.
- No fractional shares issued; cash payment in lieu at closing price on Feb 18, adjusted for split.
- Stock symbol remains INTS; new CUSIP 45828J 202.

## SEC filing metadata
- accession: 0001567264-26-000007
- form_type: 8-K
- ticker: INTS
- cik: 0001567264
- company_name: INTENSITY THERAPEUTICS, INC.
- filed_at: 2026-02-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.03, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1567264/000156726426000007/0001567264-26-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1567264/000156726426000007/intensity-20260213.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001567264-26-000007
- JSON: https://secwatch.observer/filing/0001567264-26-000007.json
- Plain text: https://secwatch.observer/filing/0001567264-26-000007.txt

## Source-grounded claims
- claim_id: 824cfe5719a63592e9cf6e89e0091475a9630493
  claim: INTENSITY THERAPEUTICS, INC.: Filed amendment to certificate of incorporation to effect a 1-for-25 reverse stock split (effective 2026-02-13).
  evidence_excerpt: On February 13, 2026, Intensity Therapeutics, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware an amendment (the “Certificate of Amendment”) to its amended and restated certificate of incorporation, as amended, to effect a reverse stock split of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a ratio of 1-for-25 (the “Reverse Stock Split”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1567264/000156726426000007/0001567264-26-000007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.